Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606489 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT00606489 is a Phase 3 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT00606489, a Phase 3 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study of Caldolor administered to hospitalized adult and pediatric burn patients is to determine the efficacy of Caldolor on reducing fever when compared to placebo when administered every 6 hours for at least 24 hours.
Interventions
- DRUG Placebo
- DRUG Caldolor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606489
The ClinicalTrials.gov registry entry for NCT00606489 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00606489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606489 about?
NCT00606489 is a clinical study titled "Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients". The primary objective of this study of Caldolor administered to hospitalized adult and pediatric burn patients is to determine the efficacy of Caldolor on reducing fever when compared to placebo when administered every 6 hours for at least 24 hours.
What is the current status of trial NCT00606489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2007-11. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00606489?
The interventions under investigation include: Placebo (DRUG), Caldolor (DRUG).
Who is sponsoring clinical trial NCT00606489?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.